Orchid Pharma · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Chinese manufacturers controlling 3-4 players in 7 ACA globally could potentially engage in aggressive pricing when Indian capacity enters, though management cited stable $60 weighted average pricing for 10+ years and belief that private Chinese enterprises now seek profitability.
Cefixime is under maximum margin stress particularly in rest-of-world markets where volumes are highest and competition fiercest. Management acknowledged this product is derived from PNG where Orchid lacks backward integration, creating ongoing vulnerability.
Se Pro DCGI trial waiver outcome uncertain despite Orchid's precedent with Focablat; commercial launch timeline depends on regulatory committee decision post-application. WHO PQ process takes ~2 years.
Management acknowledged integration benefits from merger will emerge progressively, with initial visible benefits only from next financial year (FY28), creating near-term margin headwind.
